ICO.V · iCo Therapeutics Inc

-

Please sign in to comment on ICO.V

1 Comment

Admin

3 years, 7 months ago

iCo Therapeutics Inc is currently in a long term uptrend where the price is trading 31.9% above its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

iCo Therapeutics Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has increased by 62.5% to $-193K since the same quarter in the previous year.

Finally, its free cash flow grew by 70.9% to $-193K since the same quarter in the previous year.

Based on the above factors, iCo Therapeutics Inc gets an overall score of 4/5.

Industry	Biotechnology
Sector	Healthcare
ISIN	CA80401L3083
CurrencyCode	CAD
Exchange	V

Target Price	0.2
PE Ratio	None
Dividend Yield	0.0%
Market Cap	19M
Beta	2.46

ABOUT

iCo Therapeutics Inc

Satellos Bioscience Inc., a regenerative medicine company, develops small molecule drugs that restore faulty muscle regeneration in degenerative disease and muscle wasting disorders. Its lead program restores the capacity of muscle stem cells to properly divide and produce progenitor cells in Duchenne Muscular Dystrophy, a rare disease. The company was incorporated in 2012 and is based in Toronto, Canada.

ICO.V · iCo Therapeutics Inc

-

iCo Therapeutics Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest iCo Therapeutics Inc using a moving average strategy